Skip directly to site content Skip directly to page options Skip directly to A-Z link


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
														Search

		Submit


Tuberculosis (TB)


Section Navigation
			
			CDC Home


Facebook
        Twitter
        LinkedIn
        Syndicate





Report of Expert Consultations on Rapid Molecular Testing to Detect Drug-Resistant Tuberculosis in the United States										Related Pages
										Appendix 2: Roles and Responsibilities in a Regional Laboratory System for Providing for Molecular Drug-Resistance Testing for TB
CDC should establish regional laboratories to provide molecular DR testing for rifampin resistance and isoniazid resistance for TB control programs in the United States and affiliated jurisdictions. The goal is to provide sufficient testing capacity to enable molecular drug-resistance testing for (1) one AFB smear-positive or NAA-positive respiratory specimen or one *Mycobacterium tuberculosis* culture from each TB patient or TB suspect (‘universal testing’) and (2) specimens or isolates from persons that the TB Program designates as high priority for molecular DR testing (‘judicious use testing’). For universal testing, it should be noted that there were ~5000 pulmonary AFB-smear-positive TB cases reported to CDC in 2007; an approximately equal number of AFB-smear-positive specimens due to non-tuberculosis mycobacteria; and ~7,400 pulmonary and ~3000 extrapulmonary culture-confirmed TB cases reported to CDC in 2007. Thus, universal testing would entail testing 10,000 to 20,000 samples per year.
A phased approach to developing and implementing a molecular DR testing service will be needed. As a first step, it would be essential to provide molecular DR testing services for testing TB patients or suspects at high-risk of having MDR TB and those deemed high priority by the program. This could be accomplished by providing sufficient new funding to existing, proficient molecular DR testing laboratories to allow them to expand their capacities to meet this need. If done as supplements to existing cooperative agreements, this could be done quickly. These programs could also serve as pilot projects by offering universal testing for selected programs. Such an interim service would allow time to
compare the performances and costs of currently available validated molecular DR tests and select one or more for use in the molecular DR testing service;
assess and overcome potential obstacles and barriers to a regional approach to diagnostic testing such as local regulations regarding out-of-state testing, reporting requirement, and need for memoranda of agreement;
develop a strategy to coordinate or integrate services provided by the molecular DR testing laboratories and the TB genotyping laboratories to avoid unnecessary duplication of efforts and shipment of isolates;
develop a roll-out strategy for the molecular DR testing service to include informing potential service users of the availability of the service, how to access the service, and the appropriate use and interpretation of molecular DR tests for TB;
define the scope of the molecular DR testing service more precisely by providing reliable estimates of the anticipated numbers of non-processed specimens, processed specimens, and cultures to be tested;
design a molecular DR testing service to meet the needs of local and state TB control programs; and
develop, compete, and award a request for contract to provide the services.In addition to molecular DR testing, the resources of the molecular DR testing laboratory might be leveraged to provide other services for state and local TB programs and laboratories, such as NAA testing for detection, culturing, second-line drug susceptibility testing, or genotyping. The scope of any additional service must be clearly defined and adequately funded.
**Cost estimate** for 2500 samples per year (10 per day)
One laboratory needed for judicious use; a second laboratory may be needed as a backup. Four laboratories are likely to be needed for universal testing.
Estimates do not include the cost of processing specimens at the molecular DR testing laboratory.

Cost estimate for 2500 samples per year (10 per day)
**CDC**:
Shipping of isolates to molecular DR testing laboratory ($27 per isolate)
up to $67,500**Program:**
Shipping specimens to testing laboratory ($10 per specimen)
up to $50,000**Molecular DR testing laboratory:**
Consumables for molecular DR tests ($10 to $30 per sample tested)
$25,000–75,000Miscellaneous laboratory supplies ($10 per sample tested)
$25,000Personnel for (10–20 samples per day; 2500-5000 per year)
(1 FTE technician, 0.5 FTE data entry clerk, 0.5 FTE laboratory manager)
$200,000Overhead (amount depends on site) estimate 20%
$50,000–60,000Molecular DR testing laboratory subtotal:
$300,000–360,000Initial equipment (amount depends on method)
CDC Responsibilities
Develop a request for contract (RFC) that specifies the duties and responsibilities of the regional molecular DR testing laboratories and the proposal evaluation criteria. Advertise and compete the RFC. Review applications and select successful offerors. Provide funds.
Develop and fund a process (e.g., ‘bill-to-recipient’ FedEx account) for shipping *M. tuberculosis* cultures to the regional molecular DR testing laboratories.
Develop and fund a process for shipping specimens to the regional molecular DR testing laboratories for public health laboratories or programs that can not afford the cost of shipping specimens.
Provide guidance, templates, or models to assist TB Programs to develop criteria for selecting TB suspects or patients for molecular DR testing and develop and implement protocols for accessing the regional molecular DR testing services.
Work with molecular DR testing laboratories to develop standardized reporting.
Work with molecular DR testing laboratories to develop an external quality assurance, proficiency testing, or rechecking program for the molecular DR testing laboratories.
Develop a robust process for monitoring and evaluating the performance of the molecular DR testing laboratories. This should include post-market surveillance of the molecular DR testing to determine the performance, cost, and benefit of the molecular DR testing in a high-throughput setting.
Work with regional laboratories and programs to develop protocols to analyze discrepancies in the results of molecular and conventional DS tests. Serve as a referee laboratory to analyze discrepant results. Collect data on and investigate all discrepancies to better understand the performance of molecular and conventional DS testing.
Provide additional molecular and conventional DS testing for samples determined to be rifampin resistant.
Provide technical assistance and consultation.Regional Molecular DR Testing Laboratory Responsibilities
Design and implement a molecular DR testing service to detect rifampin resistance and isoniazid resistance. The service should include
protocols and standard forms for submitting specimens for testing,
for universal testing, acceptable specimens should include non-processed respiratory specimens from TB suspects or patients who produced an AFB smear-positive or NAA positive specimen, processed AFB smear-positive respiratory specimens (sediments) from TB suspects or patients, and AFB-positive cultures from TB suspects or patients;
specimens (respiratory or non-respiratory) or cultures identified by the TB program as high priority for molecular DR testing are acceptable.
protocols for accessioning samples and entering data in a laboratory information management system;
an algorithm and protocols for molecular DR testing of specimens and cultures;
include appropriate positive and negative controls
ensure that testing includes the assessment of PCR inhibitors
if inhibitors detected or suspected, appropriate follow-up testing
if results are indeterminate, appropriate follow-up testing
if an open NAA system is used, protocols to prevent end-product contamination
procedures for result review and reporting – system must maintain patient confidentiality;
a quality management system and an external quality assurance program; and
procedures for archiving samples.
Preferably provide six-day-a-week testing.
Select, establish and validate rapid molecular test(s) to detect rifampin resistance and isoniazid resistance in accord with pertinent CLIA and FDA rules and regulations.
Conduct testing and report results of molecular DR testing within 2 business days of specimen receipt for at least 90% of samples received.
Work with programs to develop and implement protocols for reporting molecular DR test results. At the discretion of the program, this may include reporting to the TB Program, TB public health laboratory, local public health officials, sample submitter, etc. Results should be reported electronically to individuals designated by TB programs. The detection of resistance should be reported by telephone to individuals designated by the TB program.
Work with each TB program to develop and implement a reflex testing protocol to expedite testing of susceptibilities to first-line and second-line drugs for all rifampin-resistant samples.
The testing may be done in the same facility as the molecular DR testing, in another laboratory proficient in drug-susceptibility testing, or the original referring laboratory.
In addition, all isolates found to be rifampin resistant should be referred to CDC for additional molecular and conventional DS testing.
Work with CDC and TB Programs to develop and implement a protocol for analyzing discrepant results.
Participate in an external quality assessment or proficiency testing program.Tuberculosis Control Program Responsibilities
Develop and implement a protocol that enables health care providers to access the molecular DR testing services in their jurisdiction. Include criteria for selecting TB suspects or patients for testing. For universal testing, criteria should allow testing of one AFB smear-positive or NAA-positive respiratory specimen or*M. tuberculosis* culture from each TB patient or TB suspect. Criteria for high priority or judicious testing might include:
Persons at risk of having MDR-TB such as persons exposed to an MDR-TB case, from a population with a high rate of MDR TB, failing or failed therapy with first-line anti-TB drugs, persons who have been previously treated for TB and relapse cases.
Specimens or isolates for which the result would alter case management or TB Control decisions, outbreak or contact investigations, preventive therapy, infection control, etc.
High profile situations needing test results in a short time frame (e.g. outbreaks in schools or congregate settings; placing persons on a ‘Do Not Board’ list).
Specimens or isolates that can not be tested easily with conventional methods such as non-viable specimens and mixed or contaminated cultures.
Ensure that health care providers are aware of the molecular DR testing service and protocol for accessing the service.
Coordinate programmatic and laboratory activities:
optimize communication between program, laboratory, and clinicians,
ensure that the public health laboratory is engaged early in the testing process for samples being submitted by other laboratories to facilitate referral and tracking of samples and expediting submission of samples to the public health laboratory, and
ensure that the public health laboratory is informed of all positive mol DS test results regardless of submitter to facilitate and expedite follow-up drug-susceptibility testing.
Develop protocols for approving requests for molecular DR testing.
Develop protocols for shipping specimens to the molecular DR testing laboratory. Work with CDC or specimen submitters to arrange for payment of costs, or pay for shipping costs if necessary.
Develop a protocol for shipping cultures to the molecular DR testing laboratory. Develop protocols for shipping specimens to the mol-DS testing laboratory. Work with CDC or specimen submitters to arrange for payment of costs, or pay for shipping costs if necessary
Designate individuals to be notified of test results or subsets of test results (e.g., negative test results, detection of *M. tuberculosis* DNA, detection of drug resistance, etc.). As appropriate, develop protocols to act upon test results.
Work with the molecular DR testing laboratory and CDC to develop and implement a reflex testing protocol that ensures prompt culture-based testing of susceptibilities to first-line and second-line drugs for all rifampin-resistant samples. Work with CDC and testing laboratories to arrange payment of the costs of the reflex testing. Cost to be paid by the TB program. For example, all rifampin-resistant isolates could be tested for susceptibility to first-line and second-line drugs at 1) the molecular DR testing facility, 2) the program’s public health laboratory, or 3) at another laboratory proficient in drug-susceptibility testing.
Develop and implement a protocol for detecting and analyzing discrepancies in the results of molecular and conventional DS tests. Work with CDC and the molecular DR testing laboratory to evaluate discrepancies.
Provide technical assistance and consultation on the appropriate use and interpretation of molecular DR tests to health care providers in their jurisdiction.Local and State Public Health Laboratories
Work with local and state TB Control Programs to ensure that clinical laboratories in their jurisdictions are aware of the molecular DR testing service and protocol for accessing it.
Coordination of programmatic and laboratory activities.
Develop protocols with TB Control Programs for shipping specimens or isolates to the molecular DR testing laboratory.
Develop protocol with TB Control Programs to detecting and analyzing discrepancies in the results of molecular and conventional tests.
Work with TB Control Programs and the molecular DR testing laboratory to develop and implement a reflex testing protocol that ensures prompt culture-based testing of susceptibilities to first-line and second-line drugs.
Work with programs to develop and implement protocols for reporting molecular DR test results.
Provide technical assistance and consultation on the interpretation of molecular DR tests to laboratorians and health care providers in their jurisdiction.Regional Training and Medical Consultation Center Responsibilities
Provide technical assistance and consultation on clinical and programmatic aspects of the appropriate use and interpretation of molecular tests for drug resistance.
Provide medical consultation as appropriate.
Develop and disseminate education material on molecular drug-resistance testing.
							
					
						Page last reviewed:  September 1, 2012					Content source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue